Movatterモバイル変換


[0]ホーム

URL:


US6787160B2 - Compositions and methods for high sorption of skin materials and delivery of sulfur - Google Patents

Compositions and methods for high sorption of skin materials and delivery of sulfur
Download PDF

Info

Publication number
US6787160B2
US6787160B2US10/327,302US32730202AUS6787160B2US 6787160 B2US6787160 B2US 6787160B2US 32730202 AUS32730202 AUS 32730202AUS 6787160 B2US6787160 B2US 6787160B2
Authority
US
United States
Prior art keywords
sulfur
skin
composition
silicon
high sorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/327,302
Other versions
US20030161895A1 (en
Inventor
Jonah Shacknai
Eugene H. Gans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=21809828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US6787160(B2)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/607,881external-prioritypatent/US6514489B1/en
Priority to US10/327,302priorityCriticalpatent/US6787160B2/en
Application filed by Medicis Pharmaceutical CorpfiledCriticalMedicis Pharmaceutical Corp
Publication of US20030161895A1publicationCriticalpatent/US20030161895A1/en
Assigned to MEDICIS PHARMACEUTICALS CORPORATIONreassignmentMEDICIS PHARMACEUTICALS CORPORATIONASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: GANS, EUGENE H., SHACKNAI, JONAH
Priority to US10/829,426prioritypatent/US6955825B2/en
Publication of US6787160B2publicationCriticalpatent/US6787160B2/en
Application grantedgrantedCritical
Assigned to GOLDMAN SACHS LENDING PARTNERS LLCreassignmentGOLDMAN SACHS LENDING PARTNERS LLCSECURITY AGREEMENTAssignors: MEDICIS PHARMACEUTICAL CORPORATION
Assigned to BARCLAYS BANK PLC, AS SUCCESSOR AGENTreassignmentBARCLAYS BANK PLC, AS SUCCESSOR AGENTNOTICE OF SUCCESSION OF AGENCYAssignors: GOLDMAN SACHS LENDING PARTNERS, LLC
Anticipated expirationlegal-statusCritical
Assigned to HUMAX PHARMACEUTICAL S.A., BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA), BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED), SOLTA MEDICAL IRELAND LIMITED, BAUSCH & LOMB MEXICO, S.A. DE C.V., Salix Pharmaceuticals, Ltd, SOLTA MEDICAL DUTCH HOLDINGS B.V., BAUSCH HEALTH COMPANIES INC., PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.), SOLTA MEDICAL, INC., SANTARUS, INC., 1261229 B.C. LTD., BAUSCH HEALTH US, LLC, SALIX PHARMACEUTICALS, INC., BAUSCH HEALTH HOLDCO LIMITED, V-BAC HOLDING CORP., BAUSCH+LOMB OPS B.V., 1530065 B.C. LTD., MEDICIS PHARMACEUTICAL CORPORATION, PRECISION DERMATOLOGY, INC., BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC), VRX HOLDCO LLC, BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC., BAUSCH HEALTH AMERICAS, INC., ORAPHARMA, INC., ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.)reassignmentHUMAX PHARMACEUTICAL S.A.RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS).Assignors: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Expired - Fee Relatedlegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

A composition and method for delivering sulfur to skin and absorbing irritants in the skin. A high sorption base is employed which comprises non-swelling clay, gum, swelling clay, silicon and combinations thereof. The absorption of the irritants does not hinder the delivery of the active ingredient to the skin.

Description

RELATED APPLICATIONS
This application is a divisional of Ser. No. 10/022,482, filed Dec. 18, 2001, which is a continuation-in-part of Ser. No. 09/607,881 filed Jun. 30, 2000, now U.S. Pat. No. 6,514,489.
FIELD OF THE INVENTION
The present invention relates to compositions and methods for absorbing the sebum, sweat, and other substances on skin and delivering sulfur can be delivered to the skin, including but not limited to the epidermis, dermis and stratum corneum.
BACKGROUND OF THE INVENTION
Skin may become irritated and certain skin disorders may be exacerbated by materials which accumulate on the skin, including but not limited to sebum (the fatty secretion of the sebaceous glands), sweat, make-up, and dirt, as well as residue from cosmetics and pharmaceuticals applied to the skin (collectively “skin materials”). Patients with skin disorders including but not limited to seborrhea, acne rosacea and acne vulgaris are treated with numerous solutions, lotions and creams. However, the problem of skin irritants, including but not limited to skin materials, persists even during and after use of these treatments.
SUMMARY OF THE INVENTION
This invention provides for sulfur delivery to the skin, including but not limited to stratum corneum, epidermis, and dermis, and its cutaneous absorption, while also absorbing cutaneous irritants (including but not limited to skin materials, such as components of sweat, sebum, moisture, epidermal metabolites, as well as residue from cosmetics and pharmaceuticals applied to the skin). In the prior art, these two actions have been known to oppose each other with absorption action inhibiting the delivery of sulfur or sulfur derivatives.
Sulfur (or elemental sulfur) is a chemically active element. In addition to its elemental form, sulfur forms many compounds. Forms of sulfur suitable for use in the present invention are those forms of elemental sulfur that are known to be useful in dermatological compositions, including but not limited to, colloidal, coated, enrobed, entrapped, fumed, precipitated, washed, and sublimed sulfur, milk of sulfur, and flowers of sulfur. The preferred form of elemental sulfur for use in the present invention is precipitated sulfur.
“Sulfur derivatives” refers to any composition that contains organic or inorganic sulfides, inorganic sulfites, organic or inorganic mercaptans, or any other than is being applied to the skin or hair of a user, including but not limited to cationic sulfur compounds, such as selenium sulfide, potassium sulfide, poly-potassium sulfide, poly-calcium poly-sulfide, H2S, sulfuric acid, bisulfides, sulfur dioxide, thiols, organic salts, sodium sulfacetamide, or combinations thereof (most preferably sodium sulfacetamide).
Inorganic sulfides suitable for use in connection with the present invention are those inorganic sulfides known to be useful in dermatological compositions and include, but are not limited to, selenium sulfide, sodium thiosulfate as well as those inorganic sulfides having the formula: RS, RSH, R2S, RSSR, or RSSH, wherein R is an inorganic element that can bind ionically or covalently with sulfur.
Organic sulfides suitable for use in connection with the present invention are those organic sulfides known to be useful in dermatological compositions and include, but are not limited to, those organic sulfides having the formula: RS, R2S, RSH, R′SSR′, or R′SSH, wherein R′ is an organic compound and its salts that can bind ionically or covalently with sulfur. Exemplary organic sulfides include, but are not limited to sodium thioglycolate (sodium mercaptoacetic acid), and gluathione.
Inorganic sulfites suitable for use in the present invention are those inorganic sulfites known to be useful in dermatological compositions, including but not limited to, sulfites and metabisulfites.
The carrier for active ingredients (active ingredients include but are not limited to sulfur and sulfur derivatives) must be “dermatologically acceptable” in the sense of being compatible with the active ingredients and not injurious to the subject. Carriers include those suitable for topical administration and may be prepared by methods known in the art.
Skin is defined to include the epidermis, dermis, stratum corneum or combinations thereof on a mammal, preferably human, cat or dog.
An embodiment of the present invention is a high sorption composition which comprises sulfur and one or more sulfur derivative, and one or more high sorption base. A high sorption base comprises one or more non-swelling clay, one or more gum, one or more swelling clay, one or more silicon, or combinations thereof. The high sorption base allows both the penetration of the sulfur and sulfur derivatives and delivery to the skin, and also absorbs skin irritants (or irritants), including but not limited to skin materials.
Sulfur may be delivered to the skin in a therapeutically effective manner either as elemental sulfur or as a sulfur derivative. Once delivered to the skin, the sulfur or sulfur derivative may act directly or may first be converted to another sulfur-containing chemical entity.
Clay materials are sorptive minerals characterized by low bulk density and layered lattice crystal structures. These minerals are derived from condensed forms of silicic acid, H4SiO4, where each silicon atom is surrounded by four oxygen atoms inducing a tetrahedral structure. Chains or two-dimensional sheets are formed when the tetrahedral structures are linked together by the sharing of common oxygen atoms. Clay materials are composed of such silica tetrahedral sheets with a central alumina octahedral sheet. The non-swelling clay preferably comprises Kaolin, a hydrated aluminum silicate with an approximate formula Al2O8.2SiO2.H2O, such as Vanclay. Swelling clays are known to swell to a very large extent when the dry clay is contacted with water, and include, smectites for example montmorillonite, bentonite, clinoptilolite, vermiculite, magadite, smectite, laponite, and beidellite, preferably magnesium aluminum silicate, such as Veegum Ultra by R. T. Vanderbilt Company, Inc., Norwalk, Conn.
The gum comprises a natural gum, an artificial gum or a combination thereof, preferably xanthan gum which is a high molecular weight heteropolysaccharide gum produced by a pure-culture fermentation of a carbohydrate withXanthomonas campestris, such as Keltrol CGF by Calgon Corporation, Pittsburgh, Pa.
Silicon means any composition that contains silica, colloidal silica, colloidal hydrated silica, precipitated silica, or silica gels, including but not limited to silicon dioxide.
Another embodiment includes a composition comprising water, xanthan gum, magnesium aluminum silicate, kaolin, silicon dioxide, sodium sulfacetamide, sodium thiosulfate, glyceryl stearate, PEG-100 stearate, quillaia saponaria extract, benzyl alcohol, and sulfur.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is not to be limited by any mechanism described in the specification, because it is defined by the claims.
One embodiment of the present invention is a composition comprising sulfur, one or more sulfur derivatives, such as sodium sulfacetamide, sulfites, mercaptans or combinations thereof (preferably sodium sulfacetamide), and a pharmaceutically acceptable carrier which comprises a high sorption base. When the composition is deposited on animal skin, preferably human skin, the sulfur and sulfur derivatives may be converted on, within or both on and within the skin surface layers by skin materials, such as sebum, moisture and sweat components into sulfur derivatives. These sulfur derivatives may have antimicrobial, antifungal, antiparasitic or a mixture of benefits. The composition absorbs the irritants such as skin materials.
In another embodiment, a high sorption base comprises one or more non-swelling clays (including but not limited to kaolin), one or more swelling clays (including but not limited to montmorillonite clays, preferably magnesium aluminum silicate, bentonite, hectorite (such as Bentone® 38 which is dimethyldistearyl ammonium hectorite by Rheox, Inc., Hightstown, N.J., and which is a suspending agent/non-surfactant and a solvent/viscosity reducing agent, and surface reactive montmorillonite), (including but not limited to stearalkonium hectorites), one or more natural gums (including but not limited to xanthan gum, guar gum, gum arabic, carrageenan and alginates), one or more non-ionic surfactants (including but not limited to stearates, palmitostearates, glycerides, sorbitan esters, polyoxyethylene ethers, polyoxyethylene glycol esters, C20-C24glyceryls and emulsifying waxes) and one or more hydrophilic solvents (including but not limited to water, glycerin, propylene glycol and polyethylene glycol).
One embodiment of the present invention comprises a method for absorbing irritants from the skin and delivering sulfur to the skin. A composition of sulfur, one or more sulfur derivatives, such as sodium sulfacetamide, sulfites, mercaptans or combinations thereof (most preferably sodium sulfacetamide), and a high sorption base with a pH of from about 6.5 to about 8.1 is topically applied to the effected skin. The high sorption base comprises non-swelling clay, gum, swelling clay, silicon or combinations thereof. The non-swelling clay is present preferably at about 15-20%, more preferably at about 18.00% (all percents are weight percents). The gum is present preferably at about 0.20-1.00%, more preferably at about 0.30%. The swelling clay is present preferably at about 1.00-2.00%, more preferably at about 1.50%. The silicon is present preferably at about 0.00-10.00%, more preferably at about 5.00%. The composition is applied to the skin, absorbs irritants from the skin, and delivers sulfur to the skin. The delivered sulfur may be from the sulfur, sulfur derivatives or a combination thereof.
Another embodiment includes a composition comprising water, xanthan gum, magnesium aluminum silicate, kaolin, silicon dioxide, sodium sulfacetamide, sodium thiosulfate, glyceryl stearate, PEG-100 stearate, quillaia saponaria extract (such as Vegetol® Bois de Panama which is a propylene glycol and water mixture or Quillaia Vegetol® GR-038 Hydro by Gattefosse S. A., Saint Priest Cedex, France), benzyl alcohol, and sulfur. The glyceryl stearate and PEG-100 stearate (such as Lipomulse® 165 by Lipo Chemicals, Inc. Paterson, N.J.) have emollient, emulsifying and surfactant qualities. The high sorption base in this invention promotes absorption of irritants but does not inhibit the delivery of the active ingredient, sulfur derivatives, to the skin.
Another embodiment of the invention is a method for enhancing absorption of sulfur in skin. A composition of sulfur, one or more sulfur derivatives, preferably sodium sulfacetamide, sulfites, mercaptans or combinations thereof (most preferably sodium sulfacetamide), and a high sorption base, with a pH of from about 6.5 to about 8.1 is topically applied to the effected skin. The sulfur derivative is preferably present at about 10%-15% by weight. The sulfur may be absorbed in the skin; and may be from the sulfur, sulfur derivatives or combinations thereof.
Another embodiment of the present invention is a method of delivering sulfur (from the sulfur, sulfur derivatives, or combinations thereof in the composition) to the skin and absorbing irritants including but not limited to skin materials from the facial skin of a human subject. A composition of sulfur, one or more sulfur derivatives, preferably sodium sulfacetamide, sulfites, mercaptans or combinations thereof (most preferably sodium sulfacetamide), and a high sorption base with a pH of from about 6.5 to about 8.1 is topically applied to the effected skin. The sulfur is preferably at about 5% and an additional sulfur derivative is preferably present at about 10%.
EXAMPLE 1
One embodiment of the present invention is the following preferred composition.
CTFA NamePercent w/w
Phase A
Purified Water41.76 
Xanthan Gum NF0.30
Phase B
Kaolin USP18.00 
Silicon Dioxide NF5.00
Sulfacetamide Sodium USP11.29 
Sodium Thiosulfate0.10
Phase C
Glyceryl Stearate & PEG-100 Stearate10.00 
Quillaia Saponaria Extract1.00
Benzyl Alcohol NF1.00
Phase D
Precipitated Sulfur USP5.00
Phase E
Witch Hazel (14% Alcohol)5.00
Fragrance 271600.05
EXAMPLE 2
A composition according to the invention containing 5% (radiolabeled) sulfur in addition to sodium sulfacetamide was applied at real-life use levels to the surface of wetted excised human skin mounted in a skin penetration cell. After 12 hours, the skin was rinsed and wiped off, and a second dose was then applied for an additional 12 hours. Then, the radiolabeled sulfur was determined (a) on the surface of and within the stratum corneum; (b) within the epidermis and within the dermis; and (c) within the reservoir (the reservoir was designed to emulate the blood circulation below the skin) underneath the skin which represents the amount passing through the skin.
The present invention in another embodiment may be used to deliver sulfur below the dermis and epidermis and systemically as evidenced in the data regarding the reservoir.
The following table shows the results from this example:
Micrograms of Sulfur Deposited
On the StratumWithin the
CorneumStratumIn theIn theIn the
SurfaceCorneumEpidermisDermisReservoir
13442951172726
Over 25% of the applied dose of sulfur has been absorbed below the surface of the stratum corneum. These are the critical areas because lesions and inflammation occur in the stratum corneum, epidermis and dermis, and the composition is useful for treatment and prevention of lesions and inflammation.
EXAMPLE 3
Four high sorption treatment formulations, containing radio-labeled sulfur (S35), which are set forth in the following tables, in addition to sodium sulfacetamide, were applied at real-life use levels to the surface of wetted, excised human skin mounted in a skin penetration cell. Each treatment was left on the skin for 20 minutes before being rinsed and wiped off once. After 12 hours, a second dose of each formulation was then applied for an additional 20 minutes, then rinsed and wiped off once.
At 24 hours, the skin was removed from each cell and the amount of radio-labeled sulfur was determined: (a) on the surface of and within the stratum corneum; (b) within the epidermis and within the dermis; and (c) within the reservoir underneath the skin which represents the amount passing through the skin.
CTFA NamePercent w/w
Formula A
Purified Water41.76
Xanthan Gum NF0.30
Magnesium Aluminum Silicate1.50
Kaolin USP18.00
Silicon Dioxide NF5.00
Sulfacetamide Sodium USP11.29
Sodium Thiosulfate0.10
Glyceryl Stearate & PEG-100 Stearate10.00
Quillaia Saponaria Extract1.00
Benzyl Alcohol NF1.00
Precipitated Sulfur USP5.00
Witch Hazel (14% alcohol)5.00
Fragrance 271600.05
CTFAPercent w/w
Formula B
Distilled water41.76
Xanthan Gum NF0.30
Magnesium Aluminum Silicate1.50
Glyceryl Stearate & PEG 100 Stearate10.00
Quillaia Extract1.00
Benzyl Alcohol1.00
Kaolin USP18.00
Silicon Dioxide2.00
Sulfacetamide Sodium USP11.29
Sodium Thiosulfate0.10
Precipitated Sulfur USP5.00
Silicon Dioxide3.00
Witch Hazel (14% alcohol)5.00
Fragrance 271600.05
Formula C
Distilled Water46.76
Xanthan Gum NF0.30
Magnesium Aluminum Silicate1.50
Glyceryl Stearate & PEG 100 Stearate10.00
Quillaia Saponaria Extract (e.g. Vegetol ®1.00
Bois de Panama)
Benzyl Alcohol NF1.00
Kaolin USP18.00
Sulfacetamide Sodium USP11.29
Sodium Thiosulfate0.10
Precipitated Sulfur5.00
Witch Hazel (14% alcohol)5.00
Fragrance 271600.50
Formula D
Distilled water46.76
Xanthan gum NF0.30
Magnesium Aluminum Silicate1.50
Glyceryl Stearate & PEG 100 Stearate10.00
Quillaia saponaria extract (e.g. Vegetol ®1.00
Bois de Panama)
Benzyl alcohol NF1.00
Kaolin USP16.00
Hectorite (e.g. Bentone ® 38)2.00
Sulfacetamide Sodium USP11.29
Sodium Thiosulfate0.10
Precipitated Sulfur5.00
Witch Hazel (14% alcohol)5.00
Fragrance 271600.05
The following table displays the data in micrograms of sulfur delivered to the skin by the four high sorption formulations.
On StratumWithin the
CorneumStratumIn theIn theIn the
SurfaceCorneumEpidermisDermisReservoir
A 9.614.422.05.75.5
B21.514.613.24.55.0
C24.210.421.04.95.6
D 9.713.313.03.74.5
The sulfur released by each of the formulations was substantial and readily measurable.
Finally, except for the amounts of sulfur left on the stratum corneum's surface which were not absorbed or bioavailable, there is little difference between Formula A, and Formula B, C and D. Thus, the high absorbency formulations did not impair the cutaneous bioavailability of sulfur.
It is understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are evident from a review of the following claims.

Claims (9)

What is claimed is:
1. A method for enhancing absorption of sulfur in skin comprising
Applying a composition, wherein the composition comprises one or more high sorption bases, sulfur at about 5% and sodium sulfacetamide at about 10 to 15%, wherein the high sorption base comprises one or more compounds selected from the group consisting of non-swelling clay at about 15 to 20% and silicon at about 0.00 to 10.00%; and
Absorbing sulfur in the skin, wherein the skin is one or more selected from the group consisting of epidermis, dermis, and stratum corneum.
2. The method ofclaim 1 wherein the composition has a pH of about 6.5 to about 8.1.
3. The method ofclaim 1 wherein the non-swelling clay is a hydrated aluminum silicate.
4. The method ofclaim 1 wherein the non-swelling clay is kaolin.
5. The method ofclaim 1 wherein the silicon is one or more compounds selected from the group consisting of silica, colloidal silica, colloidal hydrated silica, precipitated silica, silica gels, and silicon dioxide.
6. The method ofclaim 5 wherein the silicon is silicon dioxide.
7. The method ofclaim 1 wherein the composition further comprises water.
8. The method ofclaim 7 wherein the water is present at about 40-50%.
9. The method ofclaim 1 wherein the silicon is present at about 5.00%.
US10/327,3022000-06-302002-12-20Compositions and methods for high sorption of skin materials and delivery of sulfurExpired - Fee RelatedUS6787160B2 (en)

Priority Applications (2)

Application NumberPriority DateFiling DateTitle
US10/327,302US6787160B2 (en)2000-06-302002-12-20Compositions and methods for high sorption of skin materials and delivery of sulfur
US10/829,426US6955825B2 (en)2000-06-302004-04-21Compositions and methods for high sorption of skin materials and delivery of sulfur

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US09/607,881US6514489B1 (en)2000-06-302000-06-30Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
US10/022,482US6855342B2 (en)2000-06-302001-12-18Compositions and methods for high sorption of skin materials and delivery of sulfur
US10/327,302US6787160B2 (en)2000-06-302002-12-20Compositions and methods for high sorption of skin materials and delivery of sulfur

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US10/022,482DivisionUS6855342B2 (en)2000-06-302001-12-18Compositions and methods for high sorption of skin materials and delivery of sulfur

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US10/829,426ContinuationUS6955825B2 (en)2000-06-302004-04-21Compositions and methods for high sorption of skin materials and delivery of sulfur

Publications (2)

Publication NumberPublication Date
US20030161895A1 US20030161895A1 (en)2003-08-28
US6787160B2true US6787160B2 (en)2004-09-07

Family

ID=21809828

Family Applications (3)

Application NumberTitlePriority DateFiling Date
US10/022,482Expired - Fee RelatedUS6855342B2 (en)2000-06-302001-12-18Compositions and methods for high sorption of skin materials and delivery of sulfur
US10/327,302Expired - Fee RelatedUS6787160B2 (en)2000-06-302002-12-20Compositions and methods for high sorption of skin materials and delivery of sulfur
US10/829,426Expired - Fee RelatedUS6955825B2 (en)2000-06-302004-04-21Compositions and methods for high sorption of skin materials and delivery of sulfur

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
US10/022,482Expired - Fee RelatedUS6855342B2 (en)2000-06-302001-12-18Compositions and methods for high sorption of skin materials and delivery of sulfur

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
US10/829,426Expired - Fee RelatedUS6955825B2 (en)2000-06-302004-04-21Compositions and methods for high sorption of skin materials and delivery of sulfur

Country Status (10)

CountryLink
US (3)US6855342B2 (en)
EP (1)EP1467701A4 (en)
JP (1)JP2005513070A (en)
CN (1)CN1606430A (en)
AU (1)AU2002362118A1 (en)
BR (1)BR0215053A (en)
CA (1)CA2471260A1 (en)
IL (1)IL162396A0 (en)
MX (1)MXPA04006018A (en)
WO (1)WO2003051979A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040202729A1 (en)*2000-06-302004-10-14Jonah ShacknaiCompositions and methods for high sorption of skin materials and delivery of sulfur
US20040259744A1 (en)*2003-12-192004-12-23Meidong YangSkin and hair cleansers containing sulfur
WO2008116147A2 (en)2007-03-212008-09-25Colgate-Palmolive CompanyStructured compositions comprising a clay
US20100249683A1 (en)*2009-03-302010-09-30Aaron Matthew NobleAdjustable hinge
WO2011079160A2 (en)2009-12-232011-06-30Colgate-Palmolive CompanyVisually patterned and oriented compositions
US20200206264A1 (en)*2013-03-152020-07-02Cda Research Group, Inc.Methods of treatment using topical copper ion formulations
US11717535B2 (en)2013-03-152023-08-08Cda Research Group, Inc.Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11857514B2 (en)2013-03-152024-01-02Cda Research Group, Inc.Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US12171867B2 (en)2013-03-152024-12-24Cda Research Group, Inc.Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ES2371026T3 (en)2001-10-192011-12-26Atritech, Inc. ADJUSTABLE OCLUSION DEVICE IN THE LEFT HEADPHONE OREJUELA.
US6977081B1 (en)2002-12-182005-12-20Upsher-Smith Laboratories, Inc.Facial cream composition containing allantoin
CN100353931C (en)*2003-06-232007-12-12周彦忠Skin-care bath products and its uses
US20080145455A1 (en)*2006-12-132008-06-19Bedard Robert LCombination of Inorganic Hemostatic Agents with Other Hemostatic Agents
WO2010079513A2 (en)*2009-01-072010-07-15Sanjay BanerjiPainless treatment of warts, corns & callus
JP2014526511A (en)*2011-09-142014-10-06ヌエヴァス オルタナティヴァス ナチュラルズ,エス.エー.ピー.アイ.デ シー.ブイ. Preparation and composition of highly bioavailable zero-valent sulfur and uses thereof
FR3146804A1 (en)*2023-03-212024-09-27L'oreal COMPOSITIONS AND METHODS FOR REMOVING COLOR FROM HAIR

Citations (12)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3634264A (en)1967-11-021972-01-11Univ CaliforniaMethod and composition for cleansing hair of animals
WO1982004393A1 (en)1981-06-121982-12-23Rorer Int OverseasMethod and composition for treating acne
US4587123A (en)1984-06-281986-05-06Price Jacqueline SCompositions and methods for reducing pest infestation
US4752472A (en)1986-03-251988-06-21Exovir, Inc.Cosmetic skin treatment useing cyanoacrylate polymer film
JPH032124A (en)1989-05-301991-01-08Terumo CorpLiquid agent for external application
WO1992005764A1 (en)1990-09-281992-04-16The Procter & Gamble CompanyImproved shampoo compositions
EP0576287A1 (en)1992-06-251993-12-29Unilever PlcCosmetic compositions
US5344971A (en)1992-10-151994-09-06L'orealProcess for deodorizing a mercapto acid by extracting malodorous compound therefrom with a supercritical fluid
WO1998004241A2 (en)1996-07-251998-02-05The Procter & Gamble CompanyShampoo compositions
WO1998047466A2 (en)1997-04-181998-10-29I.V. Pharma S.A.S.The use of thioglycolic acid as depigmenting agent
WO1999024003A1 (en)1997-11-101999-05-20The Procter & Gamble CompanyCompositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil
US6429231B1 (en)2001-09-242002-08-06Bradley Pharmaceuticals, Inc.Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JPS55160721A (en)*1979-06-021980-12-13Tokyo Tanabe Co LtdPulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent
RO87009B1 (en)*1983-05-091985-06-01Octavian PlesaHair shampoo containing plant extracts
JPS61254525A (en)*1985-05-011986-11-12Rooto Seiyaku KkRemedy for pimple blended with 11alpha-hydroxy-progesterone
US5330980A (en)*1992-08-251994-07-19Shin Jae SMedicament for the topical treatment of skin
US5445823A (en)*1994-10-201995-08-29The Procter & Gamble CompanyDermatological compositions and method of treatment of skin lesions therewith
JP3605746B2 (en)*1998-02-122004-12-22株式会社コーセー Acne cosmetics
US20020164381A1 (en)*2000-06-302002-11-07Medicis Pharmaceutical CorporationMitocidal compositions and methods
US6514489B1 (en)*2000-06-302003-02-04Medicis Pharmaceutical Corp.Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
US6855342B2 (en)*2000-06-302005-02-15Medicis Pharmaceutical CorporationCompositions and methods for high sorption of skin materials and delivery of sulfur

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3634264A (en)1967-11-021972-01-11Univ CaliforniaMethod and composition for cleansing hair of animals
WO1982004393A1 (en)1981-06-121982-12-23Rorer Int OverseasMethod and composition for treating acne
US4388301A (en)1981-06-121983-06-14William H. Rorer, Inc.Method and composition for treating acne
US4587123A (en)1984-06-281986-05-06Price Jacqueline SCompositions and methods for reducing pest infestation
US4752472A (en)1986-03-251988-06-21Exovir, Inc.Cosmetic skin treatment useing cyanoacrylate polymer film
JPH032124A (en)1989-05-301991-01-08Terumo CorpLiquid agent for external application
WO1992005764A1 (en)1990-09-281992-04-16The Procter & Gamble CompanyImproved shampoo compositions
EP0576287A1 (en)1992-06-251993-12-29Unilever PlcCosmetic compositions
US5344971A (en)1992-10-151994-09-06L'orealProcess for deodorizing a mercapto acid by extracting malodorous compound therefrom with a supercritical fluid
WO1998004241A2 (en)1996-07-251998-02-05The Procter & Gamble CompanyShampoo compositions
WO1998047466A2 (en)1997-04-181998-10-29I.V. Pharma S.A.S.The use of thioglycolic acid as depigmenting agent
WO1998047466A3 (en)1997-04-181999-02-11I V Pharma S A SThe use of thioglycolic acid as depigmenting agent
WO1999024003A1 (en)1997-11-101999-05-20The Procter & Gamble CompanyCompositions containing combinations of liquid polyol fatty acid polyesters and a liquid oil
US6429231B1 (en)2001-09-242002-08-06Bradley Pharmaceuticals, Inc.Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Dermatology in General Medicine," 5<th >ed., CD-ROM, 1999, Chapter 74 p. 1-16.
"Dermatology in General Medicine," 5th ed., CD-ROM, 1999, Chapter 74 p. 1-16.
Bonnar, et al., "The Demodex Mite Population in Rosacea," Journal of the American Academy of Dermatology, vol. 28, No. 3, Mar. 1993, p. 443-448.
Database WPI Section Ch, Week 198606 Derwent Publications Ltd., London, GB; AN 1986-040399 XP002245540 & RO 87 009 A (Intr Prod Cosmetice Farmec) May 30, 1985 (abstract).
Diaz-Perez, et al., "Demodex mites in Rosacea" and "Reply," Journal of the American Academy of Dermatology, vol. 30, No. 5, Part I, May 1994, p. 812-813.
Harry, R.G., Harry's Cosmeticology, pp. 558-561, 6<th >edition (1973).
Harry, R.G., Harry's Cosmeticology, pp. 558-561, 6th edition (1973).
Lin, et al., "Sulfur Revisited," Journal of the American Academy of Dermatology, vol. 18. No. 3, Mar. 1988, p. 553-558.
Maibach, et al., "Sulfur Revisited," and "Reply," Journal of the American Academy of Dermatology, vol. 23, No. 1, Jul. 1990, p. 154-156.
Marks, "Histopathology of Rosacea", Arch. Derm., vol. 100, Dec. 1969 pp 683-691.
Sojka et al, New Polymer Technology for Skin Oil Absorbers and Controlled Release, Allured's Cosmetics & Toiletries, vol. 114, No. 3 (Mar. 1999), 83-86 and 88.
The Merck Manual, Seventeenth Edition (1999), pp 811-814.

Cited By (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040202729A1 (en)*2000-06-302004-10-14Jonah ShacknaiCompositions and methods for high sorption of skin materials and delivery of sulfur
US6955825B2 (en)*2000-06-302005-10-18Medicis Pharmaceutical CorporationCompositions and methods for high sorption of skin materials and delivery of sulfur
US20040259744A1 (en)*2003-12-192004-12-23Meidong YangSkin and hair cleansers containing sulfur
EP2612647A1 (en)2007-03-212013-07-10Colgate-Palmolive CompanyStructured compositions comprising a clay
WO2008116147A2 (en)2007-03-212008-09-25Colgate-Palmolive CompanyStructured compositions comprising a clay
US20100249683A1 (en)*2009-03-302010-09-30Aaron Matthew NobleAdjustable hinge
US9033907B2 (en)2009-03-302015-05-19Aaron Matthew NobleAdjustable hinge
WO2011079160A2 (en)2009-12-232011-06-30Colgate-Palmolive CompanyVisually patterned and oriented compositions
US9408784B2 (en)2009-12-232016-08-09Colgate-Palmolive CompanyVisually patterned and oriented compositions
US20200206264A1 (en)*2013-03-152020-07-02Cda Research Group, Inc.Methods of treatment using topical copper ion formulations
US11717535B2 (en)2013-03-152023-08-08Cda Research Group, Inc.Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11857514B2 (en)2013-03-152024-01-02Cda Research Group, Inc.Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US12171867B2 (en)2013-03-152024-12-24Cda Research Group, Inc.Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US12318406B2 (en)*2013-03-152025-06-03Cda Research Group, Inc.Methods of treatment using topical copper ion formulations
US12329779B2 (en)2013-03-152025-06-17Cda Research Group, Inc.Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza

Also Published As

Publication numberPublication date
US20020132015A1 (en)2002-09-19
AU2002362118A1 (en)2003-06-30
CA2471260A1 (en)2003-06-26
US20030161895A1 (en)2003-08-28
BR0215053A (en)2004-11-23
JP2005513070A (en)2005-05-12
WO2003051979A2 (en)2003-06-26
CN1606430A (en)2005-04-13
WO2003051979A3 (en)2004-01-22
US20040202729A1 (en)2004-10-14
US6955825B2 (en)2005-10-18
EP1467701A4 (en)2006-10-11
MXPA04006018A (en)2005-03-31
US6855342B2 (en)2005-02-15
EP1467701A2 (en)2004-10-20
IL162396A0 (en)2005-11-20
AU2002362118A8 (en)2003-06-30

Similar Documents

PublicationPublication DateTitle
US6787160B2 (en)Compositions and methods for high sorption of skin materials and delivery of sulfur
US4923900A (en)Therapeutic compositions containing benzoyl peroxide
US5086075A (en)Therapeutic compositions containing benzoyl peroxide
US5002974A (en)Anesthetic/skin moisturizing composition and method of preparing same
US5753637A (en)Method of treating acne conditions
CA1124179A (en)Method for treating acne vulgaris and compositions useful for that purpose
US5898037A (en)Formulations of magnesium compounds for local application and methods of treatment using the same
US20020164381A1 (en)Mitocidal compositions and methods
US20220288134A1 (en)Composition, system and method for treating skin
JP5198846B2 (en) Methods and compositions for burned skin
KR100358421B1 (en) Topical solvents, including serine protease inhibitors
US5916574A (en)Method of treating natural poison skin conditions
KR100864129B1 (en) Local answer for acne treatment
GB2365770A (en)Antifungal ketoconazole composition for topical use
Montes et al.Low strength anthralin in psoriasis
WO1988006878A1 (en)Pharmaceutical composition containing benzoic acid ester and kit
ES2341784T3 (en) PHARMACEUTICAL COMPOSITION CONTAINING IN ASSOCIATION UBIDECARENONE, DEXPANTENOL AND CHLORHEXIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME FOR CUTANEOUS APPLICATION.
JPH03287529A (en)Percutaneous absorption preparation of lefetamine
NZ721272B2 (en)Composition, system and method for treating skin
HK1163555A (en)Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
PT90200B (en) Process for the preparation of a moisturizing anti-inflammatory composition for the skin

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:MEDICIS PHARMACEUTICALS CORPORATION, ARIZONA

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHACKNAI, JONAH;GANS, EUGENE H.;REEL/FRAME:014464/0602;SIGNING DATES FROM 20030820 TO 20030827

FEPPFee payment procedure

Free format text:PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REFURefund

Free format text:REFUND - SURCHARGE, PETITION TO ACCEPT PYMT AFTER EXP, UNINTENTIONAL (ORIGINAL EVENT CODE: R2551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAYFee payment

Year of fee payment:4

FPAYFee payment

Year of fee payment:8

ASAssignment

Owner name:GOLDMAN SACHS LENDING PARTNERS LLC, NEW YORK

Free format text:SECURITY AGREEMENT;ASSIGNOR:MEDICIS PHARMACEUTICAL CORPORATION;REEL/FRAME:030281/0433

Effective date:20130423

ASAssignment

Owner name:BARCLAYS BANK PLC, AS SUCCESSOR AGENT, NEW YORK

Free format text:NOTICE OF SUCCESSION OF AGENCY;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS, LLC;REEL/FRAME:034749/0689

Effective date:20150108

REMIMaintenance fee reminder mailed
LAPSLapse for failure to pay maintenance fees
STCHInformation on status: patent discontinuation

Free format text:PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FPLapsed due to failure to pay maintenance fee

Effective date:20160907

ASAssignment

Owner name:1530065 B.C. LTD., CANADA

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:1261229 B.C. LTD., CANADA

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:VRX HOLDCO LLC, NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:V-BAC HOLDING CORP., CANADA

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:SOLTA MEDICAL DUTCH HOLDINGS B.V., NETHERLANDS

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.), POLAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:ORAPHARMA, INC., NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.), POLAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC., CANADA

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH US, LLC, NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA), POLAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC), HUNGARY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH HOLDCO LIMITED, IRELAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH COMPANIES INC., CANADA

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH AMERICAS, INC., NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH+LOMB OPS B.V., NETHERLANDS

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH & LOMB MEXICO, S.A. DE C.V., MEXICO

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:SOLTA MEDICAL IRELAND LIMITED, IRELAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:HUMAX PHARMACEUTICAL S.A., COLOMBIA

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:MEDICIS PHARMACEUTICAL CORPORATION, NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:SANTARUS, INC., NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:SALIX PHARMACEUTICALS, LTD, NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:SALIX PHARMACEUTICALS, INC., NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED), IRELAND

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:PRECISION DERMATOLOGY, INC., NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408

Owner name:SOLTA MEDICAL, INC., NEW JERSEY

Free format text:RELEASE BY SECURED PARTY;ASSIGNOR:BARCLAYS BANK PLC, AS COLLATERAL AGENT;REEL/FRAME:070778/0199

Effective date:20250408


[8]ページ先頭

©2009-2025 Movatter.jp